Cizzle Biotechnology Holdings

1. 30 Sep 26
   Half-year Results

   (“Cizzle", “Cizzle Biotechnology”, the “Company” or the “Group”)

   RNS 9797668 ↗
2. 03 Aug 26
   Laboratory Expansion to Accelerate Sales in USA

   Further Laboratory Expansion to Accelerate Sales in USA

   RNS 9701677 ↗
3. 22 Jul 26
   Update on Sales in USA

   Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to note that the Company's North American licensing partner Cizzle Bio Inc ("BIO"), has today announced the availability of the Company's proprietary CIZ1B Biomarker...

   RNS 9682205 ↗
4. 15 Jul 26
   Half Year Operational Update

   Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce the following operational update and highlights for the six months ended 30 June 2026 ("H1 2026").

   RNS 9668966 ↗
5. 30 Jun 26
   Change of Corporate Broker

   Cizzle Biotechnology is pleased to announce the appointment of Zeus Capital Limited as the Company's sole Corporate Broker with immediate effect.

   RNS 9643050 ↗
6. 16 Jun 26
   Result of AGM

   RNS 9621226 ↗
7. 16 Jun 26
   CIZ1B Test Approved For Clinical Use in USA

   CIZ1B Biomarker Test Approved For Clinical Use in USA

   RNS 9619656 ↗
8. 12 Jun 26
   Patent Granted in USA

   Cizzle Biotechnology, the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that a patent application covering the Company's core methods to measure the CIZ1B lung cancer biomarker has now been allowed by the U.S.

   RNS 9614836 ↗
9. 21 May 26
   Notice of AGM

   RNS 9579691 ↗
10. 07 May 26
    Issue of Options, Salary Waivers, Incentive Plan

    Issue of Options, Salary Waivers and New Management Incentive Plan

    RNS 9555973 ↗
11. 06 May 26
    Conversion of Convertible Loan Notes

    Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that the Company has received a notice to convert £400,000 of convertible loan notes ("CLNs") held by Frazer Lang (registered in the name of Ropemaker Nominees...

    RNS 9553592 ↗
12. 30 Apr 26
    Final Results

    Final results for the year ended 31 December 2025

    RNS 9545274 ↗
13. 02 Apr 26
    £250,000 Funding Facility

    Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that it has entered into a new facility (the "Facility") to provide the Company with up to £250,000 through the potential issue of further unsecured convertible loan...

    RNS 9504374 ↗
14. 23 Feb 26
    Progress on Launch of Biomarker Test in USA

    Progress on Commercial Launch of Biomarker Test in USA

    RNS 9441299 ↗
15. 04 Feb 26
    Patent Granted in Canada

    Cizzle Biotechnology, the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian...

    RNS 9406969 ↗
16. 05 Nov 25
    £250,000 Convertible Loan Note Issue

    Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce that it has raised up to £250,000 through the issue of further unsecured convertible loan notes ("Additional Notes") to Frazer Lang, an existing investor...

    RNS 9212965 ↗
17. 05 Nov 25
    LOI with leading UK Clinical Diagnostic Group

    Letter of Intent signed with leading UK Clinical Diagnostic Group Providing Laboratory Services to the NHS

    RNS 9212799 ↗
18. 27 Oct 25
    Change of Registered Office

    RNS 9196530 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.